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Abstract
Background: To present a comprehensive approach for the management of patients with neovascular glaucoma
(NVG) aiming to preserve visual function and complement pan-retinal photocoagulation (PRP) by anti-vascular
endothelial growth factor (anti-VEGF) treatment and anti-glaucoma surgery.
Methods: This study includes a prospective, interventional case series. A process flow chart for NVG management
was designed. Totally 50 patients (51 eyes) with NVG were included. Of these, 43 patients (44 eyes) completed the
treatment process. Patients were divided into central retinal vein occlusion (CRVO) and proliferative diabetic
retinopathy (PDR) groups according to their original diagnosis. Intraocular pressure (IOP), visual function, and the
status of iris and angle neovascularization were recorded before and after treatment.
Results: Patients were followed up for 6–30 months (mean 12.2 months). The IOP of all 44 patients was effectively
controlled and was significantly less after treatment (16.68 ± 4.69 mmHg) than before treatment (42.59 ± 9.
44 mmHg, P < 0.05). Thirty-nine eyes displayed controlled IOP (≤21 mmHg) after treatment. Visual acuity improved,
to some extent, in 32 eyes (72.9 %), and 12 eyes (27.3 %) had a visual acuity better than 0.1. There was no
significant difference in IOP between the PDR and CRVO groups at the end of follow-up (P = 0.8657), but the visual
acuity in the PDR group was much better than that in the CRVO group (P = 0.0079).
Conclusions: A comprehensive therapy for NVG can effectively control IOP and preserve visual function in patients
by anti-VEGF injection and anti-glaucoma surgery.
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Background
Neovascular glaucoma (NVG), a common type of refrac-
tory glaucoma, is closely related to retinal ischemia,
which is usually secondary to proliferative diabetic retin-
opathy (PDR) and central retinal vein occlusion (CRVO).
Vascular endothelial growth factor (VEGF) is usually
released after retinal ischemia, and it can spread through
the aqueous humor to the anterior segment of the eye.
This results in the neovascularization of the iris, angle,
and connective tissue membrane and is followed by
synechia of the peripheral iris and trabecular meshwork,
which can ultimately cause increased intraocular pres-
sure (IOP) or even loss of vision [1–3].
Treatment for NVG is far from satisfactory due to the
complexity of the primary disease as well as the specifi-
city of NVG itself. Its onset is abrupt and induces IOP
to increase by a large margin, which will cause a loss of
visual function if not controlled as soon as possible.
* Correspondence: drzhaomingwei@163.com
†Equal contributors
1Department of Ophthalmology, Peking University People’s Hospital, 11
Xizhimen South Street, Xi Cheng District, Beijing 100044, China
2Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing,
China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sun et al. BMC Ophthalmology  (2016) 16:150 
DOI 10.1186/s12886-016-0327-9
Commonly used anti-glaucoma drugs do not effectively
decrease IOP in NVG, and traditional anti-glaucoma
surgery is also infeasible because there is a large abun-
dance of neovessels on the surface of the iris and angle,
and damaging these vessels can lead to intraoperative
bleeding during surgery. In addition, damage to the
blood-aqueous barrier and the leakage of plasma pro-
teins are likely to stimulate the fibrovascular membrane
to grow into the filtration egress, which will ultimate
lead to the failure of filtration surgery. Moreover, the ef-
fect of glaucoma valve implantation is also not satisfac-
tory. Although cyclocryotherapy and
cyclophotocoagulation can effectively decrease IOP, diffi-
culties exist in their precise quantitation and ocular atro-
phy and loss of vision eventually occur in many of these
patients [4–7]. Another currently popular treatment for
NVG is the injection of intravitreal anti-VEGF anti-
bodies. This is expected to directly decrease the level of
intraocular VEGF and to cause the regression of neovas-
cularization in the retina, angle, and iris. In addition, in-
travitreal bevacizumab (IVB) is currently widely used to
prevent the formation of irreversible synechia in early
rubeosis and to control IOP in patients with iris neovas-
cularization (INV) alone and in those with early stage
NVG without angle closure [5, 6, 8–10]. However, there
is still no consensus regarding the optimal management
strategy for NVG.
The core of the problem lies in determining what the
goal of NVG treatment should be: to decrease IOP or to
preserve visual function. Is it possible to abandon the
use of cyclocryotherapy or cyclophotocoagulation, which
are destructive treatments, in an affected eye that still
has visual functions [4, 11–13] ? Which treatment is key
to treating NVG: anti-VEGF medication, anti-glaucoma
surgery or complete pan-retinal photocoagulation
(PRP)? Many questions remain to be answered.
Therefore, we conducted this prospective, single cen-
ter, interventional case series study to establish a com-
prehensive treatment strategy for NVG, with a core aim
of preserving visual function and a main goal of com-
pleting PRP. Anti-VEGF injection and anti-glaucoma
surgery were used as the main methods to preserve vis-
ual function and to control IOP.
Methods
Patients
An informed consent process was established following
the guidelines of the Helsinki Declaration, and written
informed consent forms were signed by all subjects to
participate in this study. The study was approved by the
medical ethics committee of Peking University People’s
Hospital.
Fifty NVG patients (51 eyes) were recruited in this
consecutive case series study between Jan. 1, 2010 and
Dec. 31, 2012 in Department of Ophthalmology, Peking
University People’s Hospital. Forty-three patients (44
eyes) were followed up for at least 6 months after the
treatment process. Participants included 29 males (30
eyes) and 14 females (14 eyes) and ranged from 18 to
77 years old (mean age of 49.95 years old). Nineteen pa-
tients (19 eyes) had CRVO, and 24 patients (25 eyes)
had PDR. Patients were divided into CRVO and PDR
groups according to their original diagnosis, but not for
the purpose of this study. All patients were followed up
for at least 6 months after the last surgery, and patients
without surgical treatment but with a stable IOP were
also followed up for at least 6 months. Patients with re-
sidual glaucoma but with IOP controlled by an ocular
hypotensive medication were followed up for at least
3 months. The inclusion criteria for the patients were 1)
NVG was caused by retinal vascular disease, 2) an IOP ≥
24 mmHg and 3) iris and angle neovascularization, angle
open or closed. NVG patients who previously received
cyclocryotherapy or cyclophotocoagulation or in whom
NVG was caused by non-single retinal ischemia, such as
ocular ischemic syndrome, were excluded from this
study. A visual acuity measurement was obtained for
each patient according to the International Standard
Visual Acuity Chart, and IOP was measured in each pa-
tient using a Goldmann applanation tonometer. A 360°
angle examination was carried out under a gonioscopy
at the initial examination. NV of the angle can range
from fully open, partly open or complete synechia clos-
ure. Sometimes, however, the details of the angle were
hard to tell because of the corneal edema caused by the
high IOP.
Decrease IOP
Paracentesis of the anterior chamber is the premier
treatment for quickly decreasing IOP. A 26-gauge needle
was applied to puncture the anterior chamber at the in-
ferior temporal cornea limbus parallel to the iris. This
avoided hemorrhage due to quickly decreased IOP. The
aqueous was slowly released until the neovascularization
dilated and oozed. The anti-glaucoma drugs used in-
cluded: carbonic anhydrase inhibitor (orally or locally),
β-blocker, α-agonist and prostaglandin (locally). For pa-
tients at the early stage of NVG, 500 ml of 20 % manni-
tol was also applied.
Intraocular anti-VEGF injection
An intraocular bevacizumab was carried out immedi-
ately after diagnosis to decrease the VEGF concentration
in the vitreous. Bevacizumab (0.05 ml/1.25 mg, Roche,
Switzerland) was administered in this study as an anti-
VEGF medication. Intravitreous injections were per-
formed according to previously reported methods [1, 9].
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If a repeated treatment was necessary, it was adminis-
tered 4 weeks after the previous treatment [14].
Anti-glaucoma surgery with or without
phacoemulsification or vitrectomy
The initial method used for anti-glaucoma surgeries in
the study patients was trabeculectomy, as previous de-
scribed and mitomycin C were used in trabeculectomy
[3, 6]. When combined with a vitrectomy, the scleral flap
was made beforehand, and a 23G incision or a 20G
manual small incision vitrectomy technique was applied
during intraocular surgery and was followed by an anti-
glaucoma surgical procedure [15, 16]. When combined
with cataract surgery, routine phacoemulsification and
intraocular lens implantation were performed through
the same incision before trabeculectomy and iridectomy.
Pan-retinal photocoagulation
PRP was performed under a slit lamp using a U.S.
LUMENIS multi-wavelength fundus laser machine. For
those patients who reveived vitrectomy surgeries, an
introcular 810 infrared laser was used for photocoagula-
tion during the surgery, if necessary.. A level II to III re-
action for retinal photocoagulation was appropriate for
laser output power intensity, the spot size was 300 mi-
crons, the exposure time was 0.3 s, and the photocoagu-
lation scope was 0.5–1 papilla diameter (PD) on the
nasal side in the optic disc and 2 PD on the temporal
side in the macula and the left retina outside of both the
up and down vascular arcades. The choice of the laser
wavelength was based on the degree of the refractive
media opacity. A red laser was preferred for photocoagu-
lation when refractive media opacity or flame-shaped
hemorrhage due to CRVO was present. If PRP could not
be conducted due to refractive media opacity, cataract
surgery or vitrectomy combined with intraocular photo-
coagulation (with or without glaucoma surgery) were
performed under the conditions used for the previous
anti-VEGF treatment. If photocoagulation could not be
completed because of hemorrhaging in the retinal sur-
face, anti-VEGF therapy was repeated every month until
the blood was absorbed to complete photocoagulation. If
there was no significant refractive media opacity or
bleeding on the retinal surface, photocoagulation was di-
vided into two treatment periods of 500–700 points each
with an interval of 3–7 days. Whether supplemental
photocoagulation was necessary depended on the results
of analysis by fundus fluorescein angiography (FFA) at
4 weeks after the first PRP. The setting for total photo-
coagulation was 1500–2500 spots.
Statistical analyses
Data analysis was performed using SPSS software (ver-
sion 10.0). Statistical comparisons between the CRVO
group and the PDR group IOP measurements before
and after treatment were calculated using Student’s t-
test, while visual acuity comparisons between the two
groups before and after treatment were calculated using
chi-squared tests.
Results
In this prospective, interventional case series, the comple-
tion of the treatment process is demonstrated in Fig. 1.
After all efforts to decrease IOP were performed, 39
(88.6 %) of the eyes with uncontrolled IOP received tra-
beculectomy with or without phacoemulsification or vi-
trectomy. Although 7 (17.9 %) of the eyes had received a
glaucoma valve implantation for a second time and 11
(28.2 %) eyes required anti-glaucoma drug treatment
due to residual glaucoma, conditions were created so
that all 44 (100.00 %) of the patients completed PRP
using the total laser amount, which was 1500–2800
points. FFA showed no neovascular leakage. Finally, all
of the patients finished the treatment process.
After the completion of the treatment process, the
IOP of 39 (88.6 %) of the eyes was effectively controlled
(≤21 mmHg), and the patients were followed up for at
least 6 months. The IOP of the other 5 (11.4 %) eyes
was between 21 and 28 mmHg. This difference was sig-
nificant and was calculated between the mean preopera-
tive IOP (42.59 ± 9.44 mmHg) and postoperative IOP
(16.68 ± 4.69 mmHg) (t = 17.07, P < 0.05).
Because the core aim of this study was to preserve vis-
ual function, after the treatment process, 32 (72.9 %) of
the eyes showed improved visual acuity, to various de-
grees, and 12 (27.3 %) of these had a visual acuity ≥ 0.1,
9 (20.5 %) remained unchanged, and 3 (6.8 %) became
worse (Fig. 2). Three out of five eyes with no light per-
ception (NLP) at the time of diagnosis showed restored
visual acuity at the end of treatment, with visual acuity
values of 0.05, 0.04, and 0.01.
Although residual neovessels were still observed on
the surface of the iris in some cases, neovascularization
of the iris and angle had clearly regressed in all of the
patients after completion of the treatment process.
Angle examination was not conducted in most cases due
to the presence of increased IOP, corneal edema, or se-
vere symptoms of pain prior to treatment in this group.
A postoperative angle check was performed on 22 eyes,
and these showed angle openings greater than half of
the circumference in 9 cases. Of these, 3 eyes required
anti-glaucoma medication after the last follow-up. The
angle of the remaining 13 eyes was partially or totally
shut off.
Surgery complications and management
Bleeding occurred in all patients who received a trabecu-
lectomy when an iridoctomy was performed. Massive
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bleeding did not occur as a result of preoperative anti-
VEGF treatment. Seven eyes (17.9 % of the 39 eyes that
received a trabeculectomy) suffered from a mild shallow
anterior chamber and choroidal detachment after the
trabeculectomy, a condition that was recovered 7–10
days postoperatively through topical steroid and cyclo-
plegic treatment. Seven eyes had mild anterior chamber
bleeding that regressed within 1 week after the oper-
ation. One eye that received a vitrectomy combined with
a trabeculectomy suffered from vitreous hemorrhage,
and this was absorbed within 1 month. In patients who
received a glaucoma valve implantation, one case had
hyphema, which was absorbed within 2 weeks.
Eyeball massage was performed in five cases on the
first day after the trabeculectomy due to elevated IOP
because of a small amount of bleeding at the filtration
pathway. In seven other cases with a shallow anterior
chamber and mild choroidal detachment, massage was
started 7–10 days postoperatively when the anterior
chamber formed and the choroidal detachment
Fig. 1 A chart of the neovascular glaucoma treatment process
Fig. 2 Visual acuity before and after treatment. A total of 32 (72.9 %) eyes showed improved vision, to various degrees. Of these, 12 (27.3 %) had
a visual acuity ≥0.1, 9 (20.5 %) remained unchanged, and 3 (6.8 %) became worse. Of the NLP eyes at the time of diagnosis, 3 of 5 had re-
acquired their visual acuity at the end of treatment and had visual acuity values of 0.05, 0.04, and 0.01
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recovered, and these patients were taught how to self-
massage after discharge. Filtration blebs became unob-
vious in 19 (48.7 %) eyes 3 months after surgery, and 7
(17.9 %) eyes with an increased IOP that could not be
controlled received a valve implantation for a second
time.
Comparisons between the CRVO group and the PDR
group
The baseline IOP was 45.58 ± 8.15 mmHg in the CRVO
group and 41.04 ± 8.95 mmHg in the PDR group, which
was not a statistically significant difference (t = 1.73, P =
0.09). The IOP after the last follow-up was 17.53 ±
5.21 mmHg in the CRVO group and 16.04 ± 4.25 mmHg
in the PDR group, with no statistically significant differ-
ence (t = 1.04, P = 0.30). Baseline visual acuity in the
CRVO group was NLP to counting fingers (CF) in 10
(52.6 %) eyes, 0.01–0.09 in 8 (42.1 %) eyes, and better
than 0.1 in 1 (5.30 %) eye. Baseline visual acuity in the
PDR group was NLP to CF in 8 (32.0 %) eyes, 0.01–0.09
in 12 (48.0 %) eyes and better than 0.1 in 5 (20.0 %) eyes.
There was no statistically significant difference in base-
line visual acuity between the two groups (chi-squared
test, x2 = 2.925, P = 0.2316). The visual acuity in the
CRVO group after the last follow-up was NLP to CF in
3 (15.8 %) eyes, 0.01–0 .09 in 15 (78.9 %) eyes, and bet-
ter than 0.1 in 1 (5.3 %) eye. In the PDR group, visual
acuity was NLP to CF in 3 (12.0 %) eyes, 0.01–0.09 in 10
(40.0 %) eyes, and better than 0.1 in 12 (48.0 %) eyes. In
the PDR group, visual acuity after treatment was better
than visual acuity in the CRVO group, and there was a
statistically significant difference between the two groups
(chi-squared test, x2 = 9.669, P < 0.05). The proportions
of eyes with residual glaucoma after completion of the
treatment process were as follows: 6 (31.6 %) eyes con-
tinued to receive IOP-lowering medication in the CRVO
group, and 6 (24.0 %) eyes continued to receive the same
medication in the PDR group. The proportion of eyes
with of residual glaucoma in the PDR group was less
than the proportion in the CRVO group, and there was
no statistically significant difference between the two
groups (x2 = 0.3126, P = 0.5761).
Typical cases
Case 1 (Fig. 3)
A 53-year-old man presented with blurry vision in
the right eye for 6 months and pain for 12 days. The
physical examination showed that the visual acuity in
his right eye was hand movement. The IOP was
36 mmHg with right corneal edema and iris neovas-
cularization. The pupillary light reflex was slow. Vit-
reous bleeding and retinal flame-shaped hemorrhage
could be observed by fundus examination, but it was
not clear. He was diagnosed with CRVO combined
with NVG in the right eye and was enrolled into our
study for treatment. Medication was administered to
control IOP, and this was followed by an intraocular
injection of 1.25 mg of Avastin into the right eye.
However, the IOP was still beyond control
(42 mmHg). Therefore, a trabeculectomy was per-
formed 13 days later, and PRP was carried out start-
ing 10 days after the operation until the completion
of PRP at 6 weeks after the surgery. At the patient’s
follow-up at 24 months after discharge, his visual
acuity was 0.03 and his IOP was 18 mmHg in the
right eye. IOP-lowering medications were not applied
after this time.
Fig. 3 Typical examination results of a 53-year-old man diagnosed with CRVO combined with NVG in the right eye. His physical examination was
demonstrated in a and b. c showed the clinical finding after a trabeculectomy. At the patient’s follow-ups at 12 (e) and 24 (f) months after
discharge, his visual acuity was 0.03 and his IOP was 18 mmHg in the right eye. No leakage was observed in FFA (d)
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Case 2 (Fig. 4)
A 46-year-old woman with a history of diabetes for
2 months who presented with decreasing visual acuity
for 1 month and who had suffered from pain for 14 days
was admitted. In the physical examination, the visual
acuity in her left eye was 0.03. IOP was 45 mmHg, and
corneal edema and iris neovascularization were ob-
served. The pupillary light reflex was slow. Retinal exud-
ation and bleeding spots could barely be observed by
fundus examination.
He was diagnosed with PDR combined by NVG in the
left eye and enrolled into our study for treatment. First,
active medication was administered to control IOP, and
this was followed by an intraocular injection of 1.25 mg
of Avastin into the left eye. The IOP was still beyond
control (38 mmHg), so a trabeculectomy was performed
4 days later, after which the cornea then returned to
clear. PRP was performed three times for a total of 3000
points. At the end of the follow-up, at 10 months after
the patient’s discharge, her visual acuity was 0.05 and
her IOP was 20 mmHg in the left eye. No IOP-lowering
medication was applied after this time.
Discussion
This prospective, interventional study establishes a
therapy strategy for NVG as follows. First, the core
purpose of all treatments is to lower IOP and pre-
serve the patient’s visual function. Second, anti-VEGF
treatment can regress neovascularization at the iris
and anterior chamber angle, which allows optimal
conditions for intraocular surgery. Third, using anti-
glaucoma surgery with or without phacoemulsification
or vitrectomy contributes to creating the conditions
necessary for the completion of PRP. Last but not
least, a change in the current view is needed because
the nature of NVG changes after PRP is completed,
when NVG changes into general glaucoma. Thus, we
can treat residual glaucoma in a general way. In our
study, 93.2 % of the patients achieved stable or im-
proved vision, and only three eyes experienced de-
creased vision. Even more gratifying was that 12 eyes
had a visual acuity ≥0.1 after treatment. These results
were significant even in patients who had a visual
acuity ≤0.1, and especially so for those in whom the
other eye was blind. There were five eyes with NLP
at the time of diagnosis that lost their light percep-
tion (LP) within 1 week. Fortunately, three of these
eyes re-acquired some visual acuity after positive
treatment. In addition, IOP was well controlled in all
of the patients in this study [2, 9, 10, 17].
A deliberate treatment plan must be established ac-
cording to the conditions of the primary disease and the
individual characteristics of NVG. On the one hand, ef-
forts should be made to reduce IOP to protect visual
function, while on the other hand, the primary retinal
disease should be treated to improve retinal ischemia.
Preserving the maximal extent of the patient’s visual
function is the core purpose of NVG treatment [7, 11].
This requires doctors to comply with the following three
points. First, patient’s IOP must be reduced as soon as
possible to minimize the damage caused by a high IOP
on visual function. In patients, this can be achieved by
applying IOP-lowering drugs as well as anterior chamber
puncture, in some cases. If IOP cannot be well con-
trolled by anti-VEGF therapy, anti-glaucoma surgery
should be decisively performed to minimize the damage
caused by a high IOP. Second, IOP-lowering measures
should be performed throughout the treatment process.
Fig. 4 Typical examination results of a 46-year-old woman diagnosed with PDR combined with NVG. a Demonstrated in the physical examination.
The cornea returned to clear after a trabeculectomy (b, d). PRP was carried out (e). At the end of the follow-up, at 10 months after the patient’s
discharge, her visual acuity was 0.05 and her IOP was 20 mmHg in the left eye (c). No leakage was observed in FFA leakage (f)
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Close follow-up and monitoring of IOP should be per-
formed until the IOP decreases to a normal level, and it
should be kept stable. During this time, medication and
surgical treatment options should be regularly adjusted.
In our study, ciliary body destructive surgery was not ap-
plied out of consideration for the ocular atrophy caused
by difficulty with precise quantitation.
Anti-VEGF treatment is an important component of
NVG treatment strategies. The advent of anti-VEGF
therapies introduced a new concept for treating intra-
ocular neovascular disease by neutralizing VEGF and
thereby regressing intraocular neovessels [6, 7, 10,
15]. On the one hand, intraoperative bleeding is not
prone to happen during anti-glaucoma surgery, mak-
ing the success of the surgery possible. On the other
hand, anti-VEGF therapy can effectively alleviate dis-
ease progression in patients who cannot complete
PRP for various reasons. This creates an opportunity
to use photocoagulation treatment. Repeated anti-
VEGF therapy can be performed if necessary [18–21].
Anti-glaucoma surgery is a significant component in
treatments for NVG. Although filtering blebs were, in
some patients in this study, no longer obvious a few
months after anti-glaucoma surgery, PRP can be confi-
dently completed under conditions including a stable
IOP during these months. In other words, anti-glaucoma
surgery provides an effective opportunity to complete
retinal laser treatment, while avoiding the damage to vis-
ual function that can be caused by an increased IOP [8,
10, 13, 22, 23]. The optimal choice is filtration surgery,
and glaucoma valve implantation can be performed later
if filtration surgery fails; however, the converse of this se-
quence is impractical because of the formation of con-
junctival scarring.
The above measures can not only lower IOP and
thereby save visual function, they can also create the
conditions necessary for the completion of PRP. The
most effective treatment is PRP, the effect of which is
to improve the state of retinal blood circulation and
prevent it from releasing VEGF. Repressing VEGF
contributes to new vessel regression in the iris and
angle. Compared to anti-VEGF therapy, PRP radically
improves retinal ischemia and thereby inhibits VEGF
release, yet anti-VEGF drugs that are intraocularly
injected are only retained locally for a short period of
time. Therefore, they do not inhibit VEGF release in
the long-run [11, 14, 16]. Conditions should be cre-
ated that allow PRP in cases of refractive media opa-
city, such as a cataract, corneal edema caused by
increased IOP, vitreous hemorrhage, or large-scale
preretinal hemorrhage. Active surgery should be per-
formed to remove the opacified media, such as a
cataract or vitreous hemorrhage, or complete PRP
should be performed during surgery.
Conclusions
In summary, a comprehensive therapy regimen for NVG
that has the preservation of visual function as its core
purpose, complete PRP as its goal, and anti-VEGF ther-
apy and anti-glaucoma surgery as its key means can ef-
fectively control IOP and retain a portion of a patient’s
visual function.
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